News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Starts Phase 1 Trial With Oral Insulin Analogue -- Merrion Pharmaceuticals, Inc. Earns USD 2 Million Milestone Payment


12/7/2009 8:52:18 AM

DUBLIN, Ireland, Dec. 7, 2009 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a USD 2 million payment to Merrion Pharmaceuticals plc, whose GIPET(R) technology is used in the formulation of NN1952.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES